Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03179943
Recruitment Status : Recruiting
First Posted : June 7, 2017
Last Update Posted : April 18, 2019
Sponsor:
Collaborators:
Stand Up To Cancer
Van Andel Research Institute
Information provided by (Responsible Party):
Fox Chase Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : July 2022